Sign inJoin waitlistJoin the waitlist

AC

Akash Chakravartty

Credentials: ·

History

Residency
2022–2025
Medical School
2018–2022

Research

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III…
Annals of Oncology · 2021 · 209 citations
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive…
Annals of Oncology · 2025 · 100 citations
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant
Breast Cancer Research · 2023 · 78 citations

Dennis Slamon
4 papers
Emily Gilmore
3 papers
RB
Rachel Beekman
3 papers
Aditya Bardia
2 papers
Akhil Khosla
2 papers
CW
Charles Wira
2 papers
David Greer
2 papers
JB
J Beck
2 papers
Pranjal Mishra
2 papers · 1 as a resident
Sarah Perman
2 papers
AZ
Abdalrahman Zarzour
1 paper
Aida Lteif
1 paper